



vTv Therapeutics to Present at Peptide Therapeutics Symposium

10/24/16

HIGH POINT, N.C.--(BUSINESS WIRE)--Oct. 24, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that the company's Chief Scientific Officer Carmen Valcarce, Ph.D., will speak at the 11th Annual Peptide Therapeutics Symposium at the Salk Institute for Biological Studies in La Jolla, California. Dr. Valcarce will discuss vTv's oral GLP-1R program during a presentation titled "Non- Peptide GLP-1 Receptor Agonists; From Idea to Medicine." The presentation is scheduled for 3:00pm on Thursday, October 27.

GLP-1R is a well validated target for the treatment of T2DM, with multiple marketed injectable GLP-1 analogues/mimetics that provide glycemic control and weight loss in Type 2 Diabetes patients. Although several of these peptides targeting GLP-1 receptor have reached blockbuster status, their use has been limited by two major factors: 1) route of administration being injections and 2) unfavorable tolerability profile that includes nausea and vomiting.

Recognizing these drawbacks, scientists at vTv Therapeutics (vTv) have designed orally bioavailable small molecule (non-peptide) GLP-1R agonists (TTP054 and TTP273) that have a favorable tolerability profile being oral agents compared to the injectable GLP-1 analogues/mimetics. The vTv GLP-1R agonists have demonstrated efficacy in nonclinical and early stage clinical studies by improving glycemic control and reducing body weight. Additionally, vTv's compounds have shown an impressive tolerability profile in the clinic.

The on-going Phase 2 LOGRA study is assessing the safety and efficacy of TTP273 in Type 2 diabetic subjects on stable doses of metformin. The previous Phase 1b trial of TTP273 showed robust effects on postprandial and fasting glucose. In this study, all doses of TTP273 were well tolerated with no serious adverse events or evidence of significant gastrointestinal side effects. The LOGRA study is expected to read out at the end of this year.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20161024005169/en/>

Source: vTv Therapeutics

vTv Therapeutics

Investors

IR@vtvtherapeutics.com

or

Media

Nura Strong, 336-841-0300 X164

PR@vtvtherapeutics.com